Loading...
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor...
Na minha lista:
| Udgivet i: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4517667/ https://ncbi.nlm.nih.gov/pubmed/23605083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2528-8 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|